A Perspective on the Kinetics of Covalent and Irreversible Inhibition

Journal of Biomolecular Screening

Volumn 22, Issue 1, 2017, Pages 3-20

  Strelow, John M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

covalent; irreversible; kinetics; occupancy; pharmacokinetics

Indexed keywords

COVALENT INHIBITOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATE; CYTOCHROME P450; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FATTY ACID AMIDASE INHIBITOR; IMATINIB; KYNURENINE AMINOTRANSFERASE II INHIBITOR; PROTEIN; PROTEIN TYROSINE KINASE;

AREA UNDER THE CURVE; BIOCHEMICAL ANALYSIS; COVALENT BOND; DRUG CLEARANCE; DRUG DISPOSITION; DRUG IDENTIFICATION; HALF LIFE TIME; INHIBITION KINETICS; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; STRUCTURE ACTIVITY RELATION; ARTICLE; BINDING ASSAY; CONCENTRATION (PARAMETERS); DRUG DESIGN; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IC50; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; KINETICS;

ANIMALS; DRUG DISCOVERY; ENZYME INHIBITORS; HUMANS; KINETICS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85007228173     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057116671509     Document Type: Review

References (141)

1. Singh J., Petter R. C., Baillie T. A., et al. The Resurgence of Covalent Drugs. Nat. Rev. Drug Discovery 2011, 10, 307-317.
2. Robertson J. G., Mechanistic Basis of Enzyme-Targeted Drugs. Biochemistry 2005, 44, 5561-5571.
3. Kalgutkar A. S., Dalvie D. K., Drug Discovery for a New Generation of Covalent Drugs. Expert Opin. Drug Discov. 2012, 7, 561-581.
4. Drahl C., Cravatt B. F., Sorensen E. J., Protein-Reactive Natural Products. Angew Chem. Int. Ed. Engl. 2005, 44, 5788-5809.
5. Bauer R. A., Covalent Inhibitors in Drug Discovery: From Accidental Discoveries to Avoided Liabilities and Designed Therapies. Drug Discov. Today 2015, 20, 1061-1073.
6. Guenther H., Anklam E., Wenzl T., et al. Acrylamide in Coffee: Review of Progress in Analysis, Formation and Level Reduction. Food Addit. Contam. 2007, 24, 60-70.
7. Konings E. J., Ashby P., Hamlet C. G., et al. Acrylamide in Cereal and Cereal Products: A Review on Progress in Level Reduction. Food Addit. Contam. 2007, 24, 47-59.
8. Foot R. J., Haase N. U., Grob K., et al. Acrylamide in Fried and Roasted Potato Products: A Review on Progress in Mitigation. Food Addit. Contam. 2007, 24, 37-46.
9. González-Bello C., Designing Irreversible Inhibitors-Worth the Effort? ChemMedChem 2016, 11, 22-30.
10. Potashman M. H., Duggan M. E., Covalent Modifiers: An Orthogonal Approach to Drug Design. J Med Chem. 2009, 52, 1231-1246.
11. Evans D. C., Watt A. P., Nicoll-Griffith D. A., et al. Drug-Protein Adducts: An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and Development. Chem. Res. Toxicol. 2004, 17, 3-16.
12. Liebler D. C., Guengerich F. P., Elucidating Mechanisms of Drug-Induced Toxicity. Nat. Rev. Drug. Discov. 2005, 4, 410-420.
13. Williams D. P., Toxicophores: Investigations in Drug Safety. Toxicology 2006, 1, 1-11.
14. Uetrecht J., Immune-Mediated Adverse Drug Reactions. Chem. Res. Toxicol. 2009, 22, 24-34.
15. Nakayama S., Atsumi R., Takakusa H., et al. A Zone Classification System for Risk Assessment of Idiosyncratic Drug Toxicity Using Daily Dose and Covalent Binding. Drug Metab. Dispos. 2009, 37, 1970-1977.
16. Lammert C., Einarsson S., Saha C., et al. Relationship between Daily Dose of Oral Medications and Idiosyncratic Drug-Induced Liver Injury: Search for Signals. Hepatology 2008, 47, 2003-2009.
17. Mah R., Thomas J. R., Shafer C. M., Drug Discovery Considerations in the Development of Covalent Inhibitors. Bioorg. Med. Chem. Lett. 2014, 24, 33-39.
18. Liu Y., Patricelli M. P., Cravatt B. F., Activity-Based Protein Profiling: The Serine Hydrolases. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 14694-14699.
19. Patricelli M. P., Szardenings A. K., Liyanage M., et al. Functional Interrogation of the Kinome Using Nucleotide Acyl Phosphates. Biochemistry 2007, 46, 350-358.
20. Kumar S., Zhou B., Liang F., et al. Activity-Based Probes for Protein Tyrosine Phosphatases. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 7943-7948.
21. Salisbury C. M., Cravatt B. F., Activity-Based Probes for Proteomic Profiling of Histone Deacetylase Complexes. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 1171-1176.
22. Wright A. T., Song J. D., Cravatt B. F., A Suite of Activity-Based Probes for Human Cytochrome P450 Enzymes. J. Am. Chem. Soc. 2009, 131, 10692-10700.
23. Bogyo M., Verhelst S., Bellingard-Dubouchaud V., et al. Selective Targeting of Lysosomal Cysteine Proteases with Radiolabeled Electrophilic Substrate Analogs. Chem. Biol. 2000, 7, 27-38.
24. Li Y. M., Xu M., Lai M. T., et al. Photoactivated Gamma-Secretase Inhibitors Directed to the Active Site Covalently Label Presenilin 1. Nature 2000, 405, 689-694.
25. Saghatelian A., Jessani N., Joseph A., et al. Activity-Based Probes for the Proteomic Profiling of Metalloproteases. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 10000-10005.
26. Cavins J. F., Friedman M., Specific Modification of Protein Sulfhydryl Groups with Alpha,Beta-Unsaturated Compounds. J. Biol. Chem. 1968, 243, 3357-3360.
27. Tong G. C., Cornwell W. K., Means G. E., Reactions of Acrylamide with Glutathione and Serum Albumin. Toxicol. Lett. 2004, 147, 127-131.
28. Bent G. A., Maragh P., Dasgupta T., In Vitro Studies on the Reaction Rates of Acrylamide with the Key Body-Fluid Thiols L-Cysteine, Glutathione, and Captopril. Toxicol Res. 2014, 3, 445-446.
29. Böhme A., Thaens D., Paschke A., et al. Kinetic Glutathione Chemoassay to Quantify Thiol Reactivity of Organic Electrophiles-Application to Alpha, Beta-Unsaturated Ketones, Acrylates, and Propiolates. Chem. Res. Toxicol. 2009, 22, 742-750.
30. Flanagan M. E., Abramite J. A., Anderson D. P., et al. Chemical and Computational Methods for the Characterization of Covalent Reactive Groups for the Prospective Design of Irreversible Inhibitors. J. Med. Chem. 2014, 57, 10072-10079.
31. Bradshaw J. M., McFarland J. M., Paavilainen V. O., et al. Prolonged and Tunable Residence Time Using Reversible Covalent Kinase Inhibitors. Nat. Chem. Biol. 2015, 11, 525-531.
32. Serafimova I. M., Pufall M. A., Krishnan S., et al. Reversible Targeting of Noncatalytic Cysteines with Chemically Tuned Electrophiles. Nat. Chem. Biol. 2012, 8, 471-476.
33. Copeland R. A., Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists; John Wiley: Mahwah, NJ, 2013; 2nd ed.
34. Mohutsky M., Hall S. D., Irreversible Enzyme Inhibition Kinetics and Drug-Drug Interactions. Methods Mol. Biol. 2014, 1113, 57-91.
35. Ghanbari F., Rowland-Yeo K., Bloomer J. C., et al. A Critical Evaluation of the Experimental Design of Studies of Mechanism Based Enzyme Inhibition, with Implications for In Vitro-In Vivo Extrapolation. Curr. Drug Metab. 2006, 7, 315-334.
36. Kuzmič P., Solowiej J., Murray B. W., An Algebraic Model for the Kinetics of Covalent Enzyme Inhibition at Low Substrate Concentrations. Anal. Biochem. 2015, 484, 82-90.
37. Regan J., Pargellis C. A., Cirillo P. F., et al. The Kinetics of Binding to p38MAP Kinase by Analogues of BIRB 796. Bioorg. Med. Chem. Lett. 2003, 13, 3101-3104.
38. Zvonok N., Pandarinathan L., Williams J., et al. Covalent Inhibitors of Human Monoacylglycerol Lipase: Ligand-Assisted Characterization of the Catalytic Site by Mass Spectrometry and Mutational Analysis. Chem. Biol. 2008, 15, 854-862.
39. Ahn K., Johnson D. S., Fitzgerald L. R., et al. Novel Mechanistic Class of Fatty Acid Amide Hydrolase Inhibitors with Remarkable Selectivity. Biochemistry 2007, 46, 13019-13030.
40. Fry D. W., Bridges A. J., Denny W. A., et al. Specific, Irreversible Inactivation of the Epidermal Growth Factor Receptor and erbB2, by a New Class of Tyrosine Kinase Inhibitor. Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 12022-12027.
41. Perez D. I., Palomo V., Pérez C., et al. Switching Reversibility to Irreversibility in Glycogen Synthase Kinase 3 Inhibitors: Clues for Specific Design of New Compounds. J. Med. Chem. 2011, 54, 4042-4056.
42. Klüter S., Simard J. R., Rode H. B., et al. Characterization of Irreversible Kinase Inhibitors by Directly Detecting Covalent Bond Formation: A Tool for Dissecting Kinase Drug Resistance. Chembiochem 2010, 11, 2557-2566.
43. Campuzano I. D., San Miguel T., Rowe T., et al. High-Throughput Mass Spectrometric Analysis of Covalent Protein-Inhibitor Adducts for the Discovery of Irreversible Inhibitors: A Complete Workflow. J. Biomol. Screen. 2016, 21, 136-144.
44. Maurer T. S., Tabrizi-Fard M. A., Fung H. L., Impact of Mechanism-Based Enzyme Inactivation on Inhibitor Potency: Implications for Rational Drug Discovery. J. Pharm. Sci. 2000, 89, 1404-1414.
45. Lim H. K., Duczak N. Jr., Brougham L., et al. Automated Screening with Confirmation of Mechanism-Based Inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in Pooled Human Liver Microsomes. Drug Metab. Dispos. 2005, 33, 1211-1219.
46. Atkinson A., Kenny J. R., Grime K., Automated Assessment of Time-Dependent Inhibition of Human Cytochrome P450 Enzymes Using Liquid Chromatography-Tandem Mass Spectrometry Analysis. Drug Metab. Dispos. 2005, 33, 1637-1647.
47. Obach R. S., Walsky R. L., Venkatakrishnan K., Mechanism-Based Inactivation of Human Cytochrome p450 Enzymes and the Prediction of Drug-Drug Interactions. Drug Metab. Dispos. 2007, 35, 246-255.
48. 50-Shift Experiments in Assessing Time-Dependent Inhibition of CYP3A4, CYP2D6 and CYP2C9 in Human Liver Microsomes. Drug Metab. Lett. 2008, 2, 51-59.
49. 50 Shift Approach Facilitates Kinact Assay Design. Xenobiotica 2009, 39, 99-112.
50. 50 Values. J. Biomol. Screen. 2009, 14, 913-923.
51. 50 Shift Assay for Reliably Identifying CYP3A Time-Dependent Inhibitors. Drug Metab. Dispos. 2011, 39, 1054-1057.
52. Zimmerlin A., Trunzer M., Faller B., CYP3A Time-Dependent Inhibition Risk Assessment Validated with 400 Reference Drugs. Drug Metab. Dispos. 2011, 39, 1039-1046.
53. I) by Means of an Endpoint Competition Assay. Angew Chem. Int. Ed. Engl. 2015, 54, 14099-14102.
54. Cheng H., Nair S. K., Murray B. W., et al. Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants. J. Med. Chem. 2016, 10, 2005-2024.
55. Pan Z., Scheerens H., Li S. J., et al. Discovery of Selective Irreversible Inhibitors for Bruton's Tyrosine Kinase. ChemMedChem 2007, 2, 58-61.
56. Nonoo R. H., Armstrong A., Mann D. J., Kinetic Template-Guided Tethering of Fragments. ChemMedChem 2012, 7, 2082-2086.
57. Kathman S. G., Xu Z., Statsyuk A. V., A Fragment-Based Method to Discover Irreversible Covalent Inhibitors of Cysteine Proteases. J. Med. Chem. 2014, 57, 4969-4974.
58. Jöst C., Nitsche C., Scholz T., et al. Promiscuity and Selectivity in Covalent Enzyme Inhibition: A Systematic Study of Electrophilic Fragments. J. Med. Chem. 2014, 57, 7590-7599.
59. Davis B. J., Erlanson D. A., Learning from Our Mistakes: The 'Unknown Knowns' in Fragment Screening. Bioorg. Med. Chem. Lett. 2013, 23, 2844-2852.
60. Shoichet B. K., Screening in a Spirit Haunted World. Drug Discov. Today 2006, 11, 607-615.
61. McGovern S. L., Caselli E., Grigorieff N., et al. A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening. J. Med. Chem. 2002, 45, 1712-1722.
62. Guertin K. R., Setti L., Qi L., et al. Identification of a Novel Class of Orally Active Pyrimido[5,4-3][1,2,4]Triazine-5,7-Diamine-Based Hypoglycemic Agents with Protein Tyrosine Phosphatase Inhibitory Activity. Bioorg. Med. Chem. Lett. 2003, 13, 2895-2898.
63. Tjernberg A., Hallén D., Schultz J., et al. Mechanism of Action of Pyridazine Analogues on Protein Tyrosine Phosphatase 1B (PTP1B). Bioorg. Med. Chem. Lett. 2004, 14, 891-895.
64. Yi F., Regan L., A Novel Class of Small Molecule Inhibitors of Hsp90. ACS Chem. Biol. 2008, 3, 645-654.
65. Baell J., Walters M. A., Chemistry: Chemical Con Artists Foil Drug Discovery. Nature 2014, 513, 481-483.
66. Baell J. B., Holloway G. A., New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays. J. Med. Chem. 2010, 53, 2719-2740.
67. Bista M., Smithson D., Pecak A., et al. On the Mechanism of Action of SJ-172550 in Inhibiting the Interaction of MDM4 and p53. PLoS One 2012, 7, e37518.
68. Voss M. E., Carter P. H., Tebben A. J., et al. Both 5-Arylidene-2-Thioxodihydropyrimidine-4,6(1H,5H)-Diones and 3-Thioxo-2,3-Dihydro-1H-imidazo[1,5-a]indol-1-Ones Are Light-Dependent Tumor Necrosis Factor-Alpha Antagonists. Bioorg. Med. Chem. Lett. 2003, 13, 533-538.
69. Carter P. H., Scherle P. A., Muckelbauer J. K., et al. Photochemically Enhanced Binding of Small Molecules to the Tumor Necrosis Factor Receptor-1 Inhibits the Binding of TNF-Alpha. Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 11879-11884.
70. Jadhav A., Ferreira R. S., Klumpp C., et al. Quantitative Analyses of Aggregation, Autofluorescence, and Reactivity Artifacts in a Screen for Inhibitors of a Thiol Protease. J. Med. Chem. 2010, 53, 37-51.
71. Dahlin J. L., Nissink J. W., Strasser J. M., et al. PAINS in the Assay: Chemical Mechanisms of Assay Interference and Promiscuous Enzymatic Inhibition Observed during a Sulfhydryl-Scavenging HTS. J. Med. Chem. 2015, 58, 2091-2113.
72. Irwin J. J., Duan D., Torosyan H., et al. An Aggregation Advisor for Ligand Discovery. J. Med. Chem. 2015, 58, 7076-7087.
73. Lor L. A., Schneck J., McNulty D. E., et al. A Simple Assay for Detection of Small-Molecule Redox Activity. J. Biomol. Screen. 2007, 12, 881-890.
74. McCallum M. M., Nandhikonda P., Temmer J. J., et al. High-Throughput Identification of Promiscuous Inhibitors from Screening Libraries with the Use of a Thiol-Containing Fluorescent Probe. J. Biomol. Screen. 2013, 18, 705-713.
75. 2 in HTS Buffers Containing Strong Reducing Reagents-Real Hits or Promiscuous Artifacts? Curr. Opin. Chem. Biol. 2011, 15, 174-182.
76. Dahlin J. L., Baell J., Walters M. A., Assay Interference by Chemical Reactivity; Eli Lilly & Company and the National Center for Advancing Translational Sciences: Bethesda, MD, 2004. Available from: http://www.ncbi.nlm.nih.gov/books/NBK326709/
77. Arrowsmith C. H., Audia J. E., Austin C., et al. The Promise and Peril of Chemical Probes. Nat. Chem. Biol. 2015, 11, 536-541.
78. Giannetti A. M., From Experimental Design to Validated Hits a Comprehensive Walk-Through of Fragment Lead Identification Using Surface Plasmon Resonance. Methods Enzymol. 2011, 493, 169-218.
79. Navratilova I., Papalia G. A., Rich R. L., et al. Thermodynamic Benchmark Study Using Biacore Technology. Anal. Biochem. 2007, 364, 67-77.
80. Rich R. L., Myszka D. G., Higher-Throughput, Label-Free, Real-Time Molecular Interaction Analysis. Anal. Biochem. 2007, 361, 1-6.
81. Zhang R., Monsma F., Fluorescence-Based Thermal Shift Assays. Curr. Opin. Drug Discov. Dev. 2010, 13, 389-402.
82. Pantoliano M. W., Petrella E. C., Kwasnoski J. D., et al. High-Density Miniaturized Thermal Shift Assays as a General Strategy for Drug Discovery. J. Biomol. Screen. 2001, 6, 429-440.
83. Martinez Molina D., Jafari R., Ignatushchenko M., et al. Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay. Science 2013, 341, 84-87.
84. Klebe G., Applying Thermodynamic Profiling in Lead Finding and Optimization. Nat. Rev. Drug. Discov. 2015, 14, 95-110.
85. Bueno A. B., Showalter A. D., Wainscott D. B., et al. Positive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse Electrophiles. J. Biol. Chem. 2016, 291, 10700-10715.
86. Dinh M., Grunberger D., Ho H., et al. Activation Mechanism and Steady State Kinetics of Bruton's Tyrosine Kinase. J. Biol. Chem. 2007, 282, 8768-8776.
87. Lieser S. A., Shindler C., Aubol B. E., et al. Phosphoryl Transfer Step in the C-terminal Src Kinase Controls Src Recognition. J. Biol. Chem. 2005, 280, 7769-7776.
88. Lieser S. A., Aubol B. E., Wong L., et al. Coupling Phosphoryl Transfer And Substrate Interactions in Protein Kinases. Biochim. Biophys. Acta 2005, 1754, 191-199.
89. Johnson D. S., Ahn K., Kesten S., et al. Benzothiophene Piperazine and Piperidine Urea Inhibitors of Fatty Acid Amide Hydrolase (FAAH). Bioorg. Med. Chem. Lett. 2009, 19, 2865-2869.
90. Dounay A. B., Anderson M., Bechle B. M., et al. Discovery of Brain-Penetrant, Irreversible Kynurenine Aminotransferase II Inhibitors for Schizophrenia. ACS Med. Chem. Lett. 2012, 3, 187-192.
91. Schwartz P. A., Kuzmic P., Solowiej J., et al. Covalent EGFR Inhibitor Analysis Reveals Importance of Reversible Interactions to Potency and Mechanisms of Drug Resistance. Proc. Natl. Acad. Sci. U. S. A. 2014, 111, 173-178.
92. 50-Based Approaches as an Alternative Method for Assessment of Time-Dependent Inhibition of CYP3A4. Xenobiotica 2010, 40, 331-343.
93. Prime M. E., Andersen O. A., Barker J. J., et al. Discovery and Structure-Activity Relationship of Potent and Selective Covalent Inhibitors of Transglutaminase 2 for Huntington's disease. J. Med. Chem. 2012, 55, 1021-1046.
94. Fleming I., Molecular Orbitals and Organic Chemical Reactions; John Wiley: New York, 2010.
95. Bulaj G., Kortemme T., Goldenberg D. P., Ionization-Reactivity Relationships for Cysteine Thiols in Polypeptides. Biochemistry 1998, 37, 8965-8972.
96. Weerapana E., Wang C., Simon G. M., et al. Quantitative Reactivity Profiling Predicts Functional Cysteines in Proteomes. Nature 2010, 468, 790-795.
97. Knowles J. R., The Intrinsic pKa-Values of Functional Groups in Enzymes: Improper Deductions from the pH-Dependence of Steady-State Parameters. CRC Crit. Rev. Biochem. 1976, 4, 165-173.
98. Bednar R. A., Reactivity and pH Dependence of Thiol Conjugation to N-Ethylmaleimide: Detection of a Conformational Change in Chalcone Isomerase. Biochemistry 1990, 29, 3684-3690.
99. Wu J. C, Fritz L. C., Irreversible Caspase Inhibitors: Tools for Studying Apoptosis. Methods 1999, 17, 320-328.
100. Copeland R. A., Mechanistic Considerations in High-Throughput Screening. Anal. Biochem. 2003, 320, 1-12.
101. Pace N. J., Weerapana E., Diverse Functional Roles of Reactive Cysteines. ACS Chem. Biol. 2013, 8, 283-296.
102. Liu Q., Sabnis Y., Zhao Z., et al. Developing Irreversible Inhibitors of the Protein Kinase Cysteinome. Chem. Biol. 2013, 20, 146-159.
103. Truong T. H., Carroll K. S., Redox Regulation of Protein Kinases. Crit. Rev. Biochem. Mol. Biol. 2013, 48, 332-356.
104. Corcoran A., Cotter T. G., Redox Regulation of Protein Kinases. FEBS J. 2013, 280, 1944-1965.
105. Paulsen C. E., Truong T. H., Garcia F. J., et al. Peroxide-Dependent Sulfenylation of the EGFR Catalytic Site Enhances Kinase Activity. Nat. Chem. Biol. 2011, 8, 57-64.
106. Cheng H., Nair S. K., Murray B. W., Recent Progress on Third Generation Covalent EGFR Inhibitors. Bioorg. Med. Chem. Lett. 2016, 26, 1861-1868.
107. Swinney D. C., The Role of Binding Kinetics in Therapeutically Useful Drug Action. Curr. Opin. Drug Discov. Dev. 2009, 12, 31-39.
108. Swinney D. C., Biochemical Mechanisms of New Molecular Entities (NMEs) Approved by United States FDA during 2001-2004: Mechanisms Leading to Optimal Efficacy and Safety. Curr. Top. Med. Chem. 2006, 6, 461-478.
109. Lichtman A. H., Leung D., Shelton C. C., et al. Reversible Inhibitors of Fatty Acid Amide Hydrolase That Promote Analgesia: Evidence for an Unprecedented Combination of Potency and Selectivity. J. Pharmacol. Exp. Ther. 2004, 311, 441-448.
110. Fegley D., Gaetani S., Duranti A., et al. Characterization of the Fatty Acid Amide Hydrolase Inhibitor Cyclohexyl Carbamic Acid 3′-Carbamoyl-Biphenyl-3-yl Ester (URB597): Effects on Anandamide and oleoylethanolamide deactivation. J. Pharmacol. Exp. Ther. 2005, 313, 352-358.
111. Knight Z. A., Shokat K. M., Features of Selective Kinase Inhibitors. Chem. Biol. 2005, 12, 621-637.
112. Campbell R. M., Tummino P. J., Cancer Epigenetics Drug Discovery and Development: The Challenge of Hitting the Mark. J. Clin. Invest. 2014, 124, 64-69.
113. Doherty M. K., Hammond D. E., Clague M. J., et al. Turnover of the Human Proteome: Determination of Protein Intracellular Stability by Dynamic SILAC. J. Proteome Res. 2009, 8, 104-112.
114. Rowicka M., Kudlicki A., Tu B. P., et al. High-Resolution Timing of Cell Cycle-Regulated Gene Expression. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 16892-16897.
115. Gubin A.N., Koduru S., Njoroge J. M., et al. Stable Expression of Green Fluorescent Protein after Liposomal Transfection of K562 Cells without Selective Growth Conditions. Biotechniques 1999, 27, 1162-1170.
116. Megerle J. A., Fritz G., Gerland U., et al. Timing and Dynamics of Single Cell Gene Expression in the Arabinose Utilization System. Biophys. J. 2008, 95, 2103-2115.
117. Zapf C. W, Gerstenberger B. S., Xing L., et al. Covalent Inhibitors of Interleukin-2 Inducible T Cell Kinase (ITK) with Nanomolar Potency in a Whole-Blood Assay. J. Med. Chem. 2012, 55, 10047-10063.
118. Moran U., Phillips R., Milo R., SnapShot: Key Numbers in Biology. Cell 2010, 141, 1262.
119. Milo R., What Is the Total Number of Protein Molecules per Cell Volume? A Call to Rethink Some Published Values. Bioessays 2013, 35, 1050-1055.
120. Ghaemmaghami S., Huh W. K., Bower K., et al. Global Analysis of Protein Expression in Yeast. Nature 2003, 425, 737-741.
121. Albe K. R., Butler M. H., Wright B. E., Cellular Concentration of Enzymes and Their Substrates. J. Theor. Biol. 1990, 143, 163-195.
122. Wohlbold L., van der Kuip H., Miething C., et al. Inhibition of bcr-abl Gene Expression by Small Interfering RNA Sensitizes for Imatinib Mesylate (STI571). Blood 2003, 102, 2236-2239.
123. Honigberg L. A., Smith A. M., Sirisawad M., et al. The Bruton Tyrosine Kinase Inhibitor PCI-32765 Blocks B-Cell Activation and Is Efficacious in Models of Autoimmune Disease and B-Cell Malignancy. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 13075-13080.
124. Advani R. H., Buggy J. J., Sharman J. P., et al. Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients with Relapsed/Refractory B-Cell Malignancies. J. Clin. Oncol. 2013, 31, 88-94.
125. Lanning B. R., Whitby L. R., Dix M. M., et al. A Road Map to Evaluate the Proteome-Wide Selectivity of Covalent Kinase Inhibitors. Nat. Chem. Biol. 2014, 10, 760-767.
126. Monroy C. A., Doorn J. A., Roman D. L., Modification and Functional Inhibition of Regulator of G-Protein Signaling 4 (RGS4) by 4-Hydroxy-2-Nonenal. Chem. Res. Toxicol. 2013, 26, 1832-1839.
127. Rachakonda G., Xiong Y., Sekhar K. R., et al. Covalent Modification at Cys151 Dissociates the Electrophile Sensor Keap1 from the Ubiquitin Ligase CUL3. Chem. Res. Toxicol. 2008, 21, 705-710.
128. Patricelli M. P., Janes M. R., Li L. S., et al. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State. Cancer Discov. 2016, 6, 316-329.
129. Johnson D. S., Weerapana E., Cravatt B. F., Strategies for Discovering and Derisking Covalent, Irreversible Enzyme Inhibitors. Future Med. Chem. 2010, 2, 949-964.
130. Ahn K., Johnson D. S., Mileni M., et al. Discovery and Characterization of a Highly Selective FAAH Inhibitor That Reduces Inflammatory Pain. Chem. Biol. 2009, 16, 411-420.
131. Lewandowicz A., Tyler P. C., Evans G. B., et al. Achieving the Ultimate Physiological Goal in Transition State Analogue Inhibitors for Purine Nucleoside Phosphorylase. J. Biol. Chem. 2003, 278, 31465-31468.
132. Mayhew B. S., Jones D. R., Hall S. D., An In Vitro Model for Predicting In Vivo Inhibition of Cytochrome P450 3A4 by Metabolic Intermediate Complex Formation. Drug Metab. Dispos. 2000, 28, 1031-1037.
133. Ito K., Ogihara K., Kanamitsu S., et al. Prediction of the In Vivo Interaction between Midazolam and Macrolides Based on In Vitro Studies Using Human Liver Microsomes. Drug Metab. Dispos. 2003, 31, 945-954.
134. Wang Y. H., Jones D. R., Hall S. D., Prediction of Cytochrome P450 3A Inhibition by Verapamil Enantiomers and Their Metabolites. Drug Metab. Dispos. 2004, 32, 259-266.
135. Zhang X., Jones D. R., Hall S. D., Prediction of the Effect of Erythromycin, Diltiazem, and Their Metabolites, Alone and in Combination, on CYP3A4 Inhibition. Drug Metab. Dispos. 2009, 37, 150-160.
136. Zhang X., Quinney S. K., Gorski J. C., et al. Semiphysiologically Based Pharmacokinetic Models for the Inhibition of Midazolam Clearance by Diltiazem and Its Major Metabolite. Drug Metab. Dispos. 2009, 37, 1587-1597.
137. Quinney S. K., Zhang X., Lucksiri A., et al. Physiologically Based Pharmacokinetic Model of Mechanism-Based Inhibition of CYP3A by Clarithromycin. Drug Metab. Dispos. 2010, 38, 241-248.
138. Zhang X., Galinsky R. E., Kimura R. E., et al. Inhibition of CYP3A by Erythromycin: In Vitro-In Vivo Correlation in Rats. Drug Metab. Dispos. 2010, 38, 61-72.
139. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry, Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations; Food and Drug Administration: Rockville, MD, 2012.
140. European Medicine Agency (EMA), Committee for Human Medicinal Products (CHMP). Guideline on the Investigation of Drug Interactions. 2012. www.ema.europa.eu/ema
141. Claxton A. J., Cramer J., Pierce C., A Systematic Review of the Associations between Dose Regimens and Medication Compliance. Clin. Ther. 2001, 23, 1296-1310.